Eli Lilly and Co
(FRA:LLY)
€
837.6
18.2 (2.22%)
Market Cap: 743.54 Bil
Enterprise Value: 766.41 Bil
PE Ratio: 113.48
PB Ratio: 61.18
GF Score: 79/100 Eli Lilly and Co at Leerink Global Healthcare Conference Transcript
Feb 27, 2020 / 02:00PM GMT
Release Date Price:
€120.34
(-2.81%)
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst
Let's get started with the first company this morning. I'm delighted to welcome Eli Lilly to the Global Healthcare Conference. Kicking stuff for us, they are represented by Patrik Jonsson, President of U.S. Biopharma; and Mike Czapar, Director of Investor Relations. Thank you, gentlemen, for joining us.
Patrik Jonsson
Eli Lilly and Company - Senior VP & President of Lilly Bio-Medicines
Thank you very much.
Questions & Answers
Geoffrey Craig Porges;Patrik Jonsson
SVB Leerink LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst
So first of all, obviously, let's talk about psoriasis. How do you think that your psoriasis franchise is going to bear up with all of the recent entrants in multiple IL-23s, more in the pipeline? How big can this category grow? And can you continue to grow your product there?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot